InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 280 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR A Painful Breast Lump May Be Mistaken For Cancer When It’s... July 15, 2020 FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 Talk Cancer: How to have conversations that could save lives April 13, 2021 Optimistic targets aren’t enough – this is what we need to... July 19, 2023 Load more HOT NEWS 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. “Solid Stress” Keeps Immune System from Killing Off Cancer Cells in... Immune interception represents an exciting opportunity to stop cancer in its... OncoArray Links Dozens of DNA Variants to Risk for Common Cancers
